X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Dr. Reddys - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs DR. REDDYS LAB - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA DR. REDDYS LAB AUROBINDO PHARMA/
DR. REDDYS LAB
 
P/E (TTM) x 14.6 29.9 48.9% View Chart
P/BV x 3.8 2.9 128.2% View Chart
Dividend Yield % 0.4 0.9 45.1%  

Financials

 AUROBINDO PHARMA   DR. REDDYS LAB
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-17
DR. REDDYS LAB
Mar-17
AUROBINDO PHARMA/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs8953,397 26.3%   
Low Rs6222,560 24.3%   
Sales per share (Unadj.) Rs254.6856.5 29.7%  
Earnings per share (Unadj.) Rs39.378.0 50.4%  
Cash flow per share (Unadj.) Rs46.6139.9 33.3%  
Dividends per share (Unadj.) Rs2.5020.00 12.5%  
Dividend yield (eoy) %0.30.7 49.1%  
Book value per share (Unadj.) Rs160.0739.8 21.6%  
Shares outstanding (eoy) m585.88165.74 353.5%   
Bonus/Rights/Conversions ESOPBB-  
Price / Sales ratio x3.03.5 85.7%   
Avg P/E ratio x19.338.2 50.5%  
P/CF ratio (eoy) x16.321.3 76.5%  
Price / Book Value ratio x4.74.0 117.8%  
Dividend payout %6.425.7 24.8%   
Avg Mkt Cap Rs m444,390493,632 90.0%   
No. of employees `00014.022.7 61.6%   
Total wages/salary Rs m17,67831,068 56.9%   
Avg. sales/employee Rs Th10,667.86,259.0 170.4%   
Avg. wages/employee Rs Th1,264.31,369.8 92.3%   
Avg. net profit/employee Rs Th1,645.8569.7 288.9%   
INCOME DATA
Net Sales Rs m149,157141,961 105.1%  
Other income Rs m1,1591,715 67.6%   
Total revenues Rs m150,316143,676 104.6%   
Gross profit Rs m34,34324,722 138.9%  
Depreciation Rs m4,27610,266 41.7%   
Interest Rs m667634 105.2%   
Profit before tax Rs m30,55815,537 196.7%   
Minority Interest Rs m500-   
Prior Period Items Rs m0349 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7,5972,965 256.2%   
Profit after tax Rs m23,01212,921 178.1%  
Gross profit margin %23.017.4 132.2%  
Effective tax rate %24.919.1 130.3%   
Net profit margin %15.49.1 169.5%  
BALANCE SHEET DATA
Current assets Rs m92,06296,837 95.1%   
Current liabilities Rs m66,22384,199 78.7%   
Net working cap to sales %17.38.9 194.6%  
Current ratio x1.41.2 120.9%  
Inventory Days Days10673 144.5%  
Debtors Days Days6898 69.3%  
Net fixed assets Rs m62,919102,552 61.4%   
Share capital Rs m586829 70.7%   
"Free" reserves Rs m93,133121,792 76.5%   
Net worth Rs m93,719122,621 76.4%   
Long term debt Rs m1,8145,449 33.3%   
Total assets Rs m162,494218,165 74.5%  
Interest coverage x46.825.5 183.5%   
Debt to equity ratio x00 43.6%  
Sales to assets ratio x0.90.7 141.1%   
Return on assets %14.66.2 234.5%  
Return on equity %24.610.5 233.0%  
Return on capital %32.712.9 253.8%  
Exports to sales %054.6 0.0%   
Imports to sales %09.4 0.0%   
Exports (fob) Rs mNA77,520 0.0%   
Imports (cif) Rs mNA13,274 0.0%   
Fx inflow Rs m75,83881,670 92.9%   
Fx outflow Rs m30,22426,355 114.7%   
Net fx Rs m45,61355,315 82.5%   
CASH FLOW
From Operations Rs m32,78621,444 152.9%  
From Investments Rs m-17,870-18,404 97.1%  
From Financial Activity Rs m-19,153-3,692 518.8%  
Net Cashflow Rs m-4,239-1,144 370.5%  

Share Holding

Indian Promoters % 54.1 25.5 212.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 5.4 147.2%  
FIIs % 27.7 35.3 78.5%  
ADR/GDR % 0.0 18.5 -  
Free float % 10.2 15.3 66.7%  
Shareholders   69,601 75,885 91.7%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   TTK HEALTHCARE  ALEMBIC LTD  STERLING BIOTECH  ELDER PHARMA  UNICHEM LAB  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Feb 23, 2018 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS